Breaking News Instant updates and real-time market news.

CBAY

CymaBay

$12.25

0.54 (4.61%)

, CPRX

Catalyst Pharmaceuticals

$3.37

0.095 (2.90%)

07:50
02/13/18
02/13
07:50
02/13/18
07:50

SunTrust to hold a conference

2018 Orphan Drug Day to be held in New York on February 13.

CBAY

CymaBay

$12.25

0.54 (4.61%)

CPRX

Catalyst Pharmaceuticals

$3.37

0.095 (2.90%)

DRNA

Dicerna

$9.33

0.02 (0.21%)

EDIT

Editas Medicine

$32.85

-0.84 (-2.49%)

MGNX

MacroGenics

$22.72

0.06 (0.26%)

MRUS

Merus

$16.33

0.26 (1.62%)

ONCE

Spark Therapeutics

$54.08

1.53 (2.91%)

QURE

uniQure

$22.32

3.15 (16.43%)

RGNX

Regenxbio

$26.75

1.05 (4.09%)

SMMT

Summit Therapeutics

$10.80

0.2 (1.89%)

  • 13

    Feb

  • 21

    Feb

  • 26

    Feb

  • 04

    Apr

CBAY CymaBay
$12.25

0.54 (4.61%)

01/22/18
OPCO
01/22/18
NO CHANGE
OPCO
Neurocrine, CymaBay could benefit from increased M&A, says Oppenheimer
Oppenheimer analyst Jay Olson notes that driven by tax reform and cash repatriation, Biotech investors expect increased M&A activity. The analyst believes tax reform with cash repatriation will increase firepower of potential buyers, and points out that managements stated interest in targets with strategic fit. In his coverage universe, Olson believes Neurocrine (NBIX), Portola Pharmaceuticals (PTLA) and CymaBay (CBAY) shares could benefit from increased M&A based on their therapeutic areas and strategic fit.
01/25/18
ROTH
01/25/18
INITIATION
Target $27
ROTH
Buy
CymaBay assumed with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi assumed coverage of CymaBay with a Buy rating and $27 price target, noting that while its valuation can stand alone in PBC, NASH is "icing on the cake."
11/28/17
LEER
11/28/17
NO CHANGE
Target $16
LEER
Outperform
Survey suggests CymaBay Seladelpar could be 'disruptive threat,' says Leerink
Leerink analyst Joseph Schwartz raised his price target for CymaBay to $16 from $12 to reflect MEDACorp physician bullishness on Seladelpar. While the drug's interim clinical data is still relatively limited, it is sufficient to stoke physician optimism in its use for patients with second-line primary biliary cholangitis, the analyst adds. He reiterates an Outperform rating on the shares.
01/24/18
HCWC
01/24/18
NO CHANGE
Target $18
HCWC
Buy
CymaBay price target raised to $18 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for CymaBay to $18 saying he sees "multiple catalysts" to drive further value creation in 2018. Value should accrue as the seladelpar program matures and expands over next 18 months, Arce tells investors in a research note. He added the company's nonalcoholic steatohepatitis opportunity into his model after meeting with management and reiterates a Buy rating on CymaBay.
CPRX Catalyst Pharmaceuticals
$3.37

0.095 (2.90%)

12/01/17
PIPR
12/01/17
NO CHANGE
Target $8
PIPR
Overweight
Catalyst Pharmaceuticals price target raised to $8 from $6 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Catalyst Pharmaceuticals to $8 saying the positive top-line data with Firdapse and the $58M capital raise position the company for a "transformational" 2018. The analyst sees reduced clinical and regulatory risk as well as an improved commercial outlook for Firdapse. He reiterates an Overweight rating on the shares.
DRNA Dicerna
$9.33

0.02 (0.21%)

11/03/17
HCWC
11/03/17
NO CHANGE
Target $10
HCWC
Buy
Dicerna price target raised to $10 from $6 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Dicerna Pharmaceuticals to $10 saying the company partnered a single early discovery asset for over $200M in upfront and milestones. The analyst reiterates a Buy rating on the shares.
01/16/18
EVER
01/16/18
INITIATION
Target $14
EVER
Outperform
Dicerna initiated with an Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat initiated Dicerna with an Outperform and $14 price target.
02/05/18
RHCO
02/05/18
INITIATION
Target $13
RHCO
Buy
Dicerna initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Dicerna (DRNA) with a Buy rating and a price target of $13. Nash says Dicerna is a "a pure-play platform technology company" whose lead program is in a Phase I development targeting a rare disease - primary hyperoxaluria - affecting some 2,700 people in the U.S. and Europe. The analyst adds that he "would not be surprised" to see a positive outcome from Dicerna's patent litigation with Alnylam (ALNY) expected this spring.
01/16/18
01/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Axalta Coating (AXTA) resumed with an Underperform at BofA/Merrill. 2. UBS (UBS) and Credit Suisse (CS) were initiated with an Underweight at Barclays. 3. Nutrien (NTR) initiated with a Neutral at Goldman Sachs. 4. Cambrex (CBM) initiated with an Outperform at William Blair. 5. Dicerna (DRNA) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
EDIT Editas Medicine
$32.85

-0.84 (-2.49%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Editas Medicine initiated with an Overweight at Barclays
Barclays initiated Editas Medicine with an Overweight rating and a $28 price target, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
01/23/18
RHCO
01/23/18
UPGRADE
Target $45
RHCO
Buy
Editas Medicine upgraded to Buy at SunTrust on year-end clinical data
As reported earlier, SunTrust analyst Peter Lawson upgraded Editas Medicine to Buy from Hold and raised his price target to $45 from $17. The analyst cites "encouraging prior preclinical data from the LCA10 eye program suggesting clinical efficacy, as ASH 2017 presentation saw a "30% biallelic and 70% monoallelic targeted integration in Cas9 HDR-modified clones". Lawson notes that the sickle cell disease implication of the treatment is the primary driver of his model, and says the stock should work on approach to 2018 year-end clinical data.
12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
01/23/18
RHCO
01/23/18
UPGRADE
RHCO
Buy
Editas Medicine upgraded to Buy from Hold at SunTrust
MGNX MacroGenics
$22.72

0.06 (0.26%)

08/31/17
NOMU
08/31/17
NO CHANGE
Target $41
NOMU
Buy
MacroGenics abstract shows initial signs of efficacy, says Nomura Instinet
Nomura Instinet analyst Christopher Marai says last night's ESMO abstract for MacroGenics' flotetuzumab indicated initial signs of efficacy and good tolerability. The analyst is encouraged that no maximum tolerated dose/schedule was defined. He has a Buy rating on MacroGenics with a $41 price target.
03/30/17
RAJA
03/30/17
INITIATION
Target $26
RAJA
Outperform
MacroGenics initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated MacroGenics with an Outperform and a $26 price target saying it is a unique "marquee" player in the bispecific antibody space. The analyst believes the value of MacroGenics' DART platform, the newsflow from multiple trials, the potential to sign additional global marquee partners, and a cash position of $245M represent an unique opportunity.
09/01/17
RHCO
09/01/17
NO CHANGE
RHCO
MacroGenics outlook remains upbeat despite J&J decision, says SunTrust
SunTrust analyst Peter Lawson says that Johnson &Johnson's decision to return duvortuxizumab, the CD19xCD3 T cell redirecting bispecific antibody, to MacroGenics is negative for MacroGenics. However, he does not believe that the decision reflects on MacroGenics' platform. He blames the decision on the neurotoxicity side effects of the drug and increased competition in the space. Lawson reiterates a $26 price target and a Buy rating on MacroGenics.
10/25/17
LEER
10/25/17
NO CHANGE
LEER
Outperform
MacroGenics MGA012 license to Incyte 'logical deal,' says Leerink
Leerink analyst Michael Schmidt notes that MacroGenics (MGNX) and Incyte (INCY) announced that the two companies have entered into an exclusive global collaboration and license agreement for the former's MGA012, an antiPD1 antibody currently in Phase I clinical development. This analyst says that the deal reinforces his view that MacroGenics' R&D engine and broad pipeline provide for a rich set of development and business development opportunities not currently reflected in the stock. He reiterates an Outperform rating on MacroGenics' shares.
MRUS Merus
$16.33

0.26 (1.62%)

09/14/17
RBCM
09/14/17
INITIATION
Target $28
RBCM
Outperform
Merus initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams started Merus with an Outperform rating and $28 price target.
01/02/18
RBCM
01/02/18
DOWNGRADE
Target $20
RBCM
Sector Perform
Merus downgraded to Sector Perform at RBC Capital on fewer drivers in 2018
As reported earlier, RBC Capital analyst Brian Abrahams downgraded Merus to Sector Perform from Outperform and lowered his price target to $20 from $28. Abrahams says that he remains enthusiastic about the long-term potential of the company's bispecific antibody pipeline and platform, but sees fewer potential upside drivers in 2018 for the shares, as "'158 and '145 programs remain promising but still very early stage".
01/02/18
RBCM
01/02/18
DOWNGRADE
RBCM
Sector Perform
Merus downgraded to Sector Perform from Outperform at RBC Capital
03/21/17
SBSH
03/21/17
DOWNGRADE
Target $31
SBSH
Neutral
Merus downgraded to Neutral from Buy at Citi
Citi analyst Yigal Nochomovitz downgraded Merus (MRUS) to Neutral saying that while the company's fundamentals continue to look "solid," the stock is fairy valued after rallying 50% following the Incyte (INCY) deal. The analyst raised his price target for the shares to $31 from $26.
ONCE Spark Therapeutics
$54.08

1.53 (2.91%)

01/25/18
WEDB
01/25/18
NO CHANGE
Target $40
WEDB
Underperform
Spark Therapeutics price target raised to $40 from $35 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Spark Therapeutics (ONCE) to $40 from $35 saying that Luxturna licensing deal with Novartis (NVS) is a positive. However, the analyst believes long-term thesis remains unchanged, and reiterates an Underperform rating on Spark's shares.
01/25/18
CANT
01/25/18
NO CHANGE
Target $105
CANT
Overweight
Cantor reiterates $105 target on Spark Therapeutics after Novartis deal
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating on Spark Therapeutics (ONCE) with a $105 price target after the company announced a licensing and supply agreement with Novartis (NVS). The deal further emphasizes the "significant value" of Luxturna's commercial opportunity, Piros tells investors in a research note. He believes the agreement places the drug with a strong commercial partner outside the U.S. while enabling Spark to remain focused on the domestic launch and development pipeline.
02/08/18
RBCM
02/08/18
INITIATION
Target $65
RBCM
Outperform
Spark Therapeutics assumed with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay assumed coverage of Spark Therapeutics (ONCE) with an Outperform rating and a price target of $65. MacKay says the FDA approval of Luxturna and "ex-Novartis (NVS) collaboration" helps to de-risk the company's earlier-stage hemophilia and inherited retinal disease assets, calling Spark Therapeutics a "trailblazer in the gene therapy space".
02/12/18
MZHO
02/12/18
INITIATION
Target $79
MZHO
Buy
Spark Therapeutics initiated with a Buy at Mizuho
Mizuho analyst Difei Yang started Spark Therapeutics with a Buy rating and a $79 price target.
QURE uniQure
$22.32

3.15 (16.43%)

11/27/17
OPCO
11/27/17
NO CHANGE
OPCO
Oppenheimer dropping coverage of uniQure
Oppenheimer is dropping coverage of uniQure due to a reallocation of analyst resources.
02/05/18
HCWC
02/05/18
NO CHANGE
Target $28
HCWC
Buy
uniQure should be bought at current levels, says H.C. Wainwright
In a research note on uniQure titled "Seeking Alpha in a High Beta Environment," H.C. Wainwright analyst Debjit Chattopadhyay says "enough with the discount already!" uniQure, along with other gene therapy and gene editing peers, could emerge as a "compelling" stock for the long run as healthcare evolves to a differentiated and value-based commercial market, Chattopadhyay tells investors in a research note. The analyst believes the company's positioning to be the first to commercialize a once-and-done solution for Hemophilia B gives it an advantage. Chattopadhyay recommends investors initiate or add to positions in uniQure.
12/01/17
HCWC
12/01/17
INITIATION
Target $28
HCWC
Buy
uniQure initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started uniQure with a Buy rating and $28 price target. The company may be able to deliver a curative option for patients with Hemophilia B well ahead of the competition, which is likely to be disruptive to the $2B global commercial opportunity, the analyst contends.
01/03/18
JANY
01/03/18
INITIATION
Target $25
JANY
Buy
uniQure initiated with a Buy at Janney Capital
Janney analyst Yun Zhong initiated uniQure with a Buy rating and $25 price target.
RGNX Regenxbio
$26.75

1.05 (4.09%)

02/12/18
MZHO
02/12/18
INITIATION
MZHO
Neutral
Regenxbio initiated with a Neutral at Mizuho
Mizuho analyst Difei Yang started Regenxbio with a Neutral rating and $28 price target.
01/05/18
RAJA
01/05/18
NO CHANGE
Target $39
RAJA
Outperform
Regenxbio weakness a buying opportunity, says Raymond James
11/22/17
11/22/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Nutanix (NTNX) initiated with a Buy at Needham. 2. Regenxbio (RGNX) and Sangamo (SGMO) were initiated with an Overweight at Barclays. 3. Amedisys (AMED), HealthSouth (HLS), LHC Group (LHCG), and LifePoint (LPNT) were initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/17
LEHM
11/22/17
INITIATION
Target $38
LEHM
Overweight
Regenxbio initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Regenxbio with an Overweight rating and $38 price target. The analyst views the company's patent portfolio as "strong" and sees "significant upside" from its wholly owned RGX-314 program in wet age-related macular degeneration.
SMMT Summit Therapeutics
$10.80

0.2 (1.89%)

02/13/18
BTIG
02/13/18
INITIATION
Target $33
BTIG
Buy
Summit Therapeutics initiated with a Buy at BTIG
BTIG analyst Timothy Chiang initiated Summit Therapeutics with a Buy rating and a price target of $33. Chiang says the company has positioned itself for upside with two pipeline products: ezutromid for the treatment of Duchenne Muscular Dystrophy, in Phase 2 with recently announced positive interim data, and ridinilazole antibiotic for the treatment of Clostridium infections, entering Phase 3 trials. Given that the former recently showed positive proof of concept data, the analyst contends that it provides additional support for the company's utrophin modulator - a potential new treatment for all 50K patients WW who suffer from DMD. Chiang sees the next potential catalyst for the stock as the release of additional results from its phaseout Phase 2 trial in about 40 patients in Q3 of this year.
02/13/18
BTIG
02/13/18
INITIATION
Target $33
BTIG
Buy
Summit Therapeutics initiated with a Buy at BTIG
BTIG analyst Timothy Chiang started Summit Therapeutics with a Buy rating and $33 price target. The company is positioned for upside with its two pipeline products, ezutromid and ridinilazole, Chiang tells investors in a research note.
01/25/18
HCWC
01/25/18
NO CHANGE
Target $75
HCWC
Buy
H.C. Wainwright sees potential competitive advantages for Sarepta
H.C. Wainwright analyst Debjit Chattopadhyay says the "steady percolation of not so good news" that delayed the initial public offering of Solid Biosciences translates into potential competitive advantages for Sarepta Therapeutics (SRPT). In addition, the analyst believes Sarepta partner Summit Therapeutics' (SMMT) preliminary analysis this morning from its ongoing Duchenne muscular dystrophy Phase 2 study provided "mixed signals." Chattopadhyay keeps a Buy rating on Sarepta with a $75 price target. The stock in afternoon trading is up 3%, or $2.17, to $67.95.
01/25/18
HCWC
01/25/18
NO CHANGE
Target $16
HCWC
Buy
Summit Therapeutics data provide 'mixed signals,' says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says this morning's preliminary analysis from Summit Therapeutics' ongoing Duchenne muscular dystrophy Phase 2 study provides "mixed signals." There was a "compelling" decline in developmental myosin and an increase in mean utrophin protein, but these positive changes had limited readthrough into T2 MRI, 6MWT and NSAA, Chattopadhyay tells investors in a research note. The analyst believes that for the shares to "breakout," Summit needs to address its financing overhang and the 48-week readout needs to provide compelling evidence of disease stabilization. Chattopadhyay has a Buy rating on Summit Therapeutics with a $16 price target. The stock in late morning trading is up 24% to $15.14.

TODAY'S FREE FLY STORIES

MRVL

Marvell

$22.68

-0.06 (-0.26%)

, CAVM

Cavium

$87.16

-0.09 (-0.10%)

14:55
02/17/18
02/17
14:55
02/17/18
14:55
Conference/Events
Cavium to host special shareholder meeting »

Special Shareholder…

MRVL

Marvell

$22.68

-0.06 (-0.26%)

CAVM

Cavium

$87.16

-0.09 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 08

    Mar

CAVM

Cavium

$87.16

-0.09 (-0.10%)

, MRVL

Marvell

$22.68

-0.06 (-0.26%)

14:51
02/17/18
02/17
14:51
02/17/18
14:51
Conference/Events
Marvell to host special shareholder meeting »

Special Shareholder…

CAVM

Cavium

$87.16

-0.09 (-0.10%)

MRVL

Marvell

$22.68

-0.06 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

DEL

Deltic Timber

$98.45

1.77 (1.83%)

, PCH

Potlatch

$54.75

0.75 (1.39%)

14:45
02/17/18
02/17
14:45
02/17/18
14:45
Conference/Events
Potlatch to host special shareholder meeting »

Special Shareholder…

DEL

Deltic Timber

$98.45

1.77 (1.83%)

PCH

Potlatch

$54.75

0.75 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

PCH

Potlatch

$54.75

0.75 (1.39%)

, DEL

Deltic Timber

$98.45

1.77 (1.83%)

14:42
02/17/18
02/17
14:42
02/17/18
14:42
Conference/Events
Deltic Timber to host special shareholder meeting »

Special shareholder…

PCH

Potlatch

$54.75

0.75 (1.39%)

DEL

Deltic Timber

$98.45

1.77 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$20.42

0.67 (3.39%)

09:31
02/17/18
02/17
09:31
02/17/18
09:31
Periodicals
Snap CEO sold $50M in stock this week, Recode reports »

Snap CEO Evan Spiegel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

, MPSYY

MorphoSys

$46.29

1.29 (2.87%)

09:27
02/17/18
02/17
09:27
02/17/18
09:27
Hot Stocks
Galapagos NV, MorphoSys present results from Phase 1 study with MOR106 in AD »

Galapagos NV (GLPG) and…

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

MPSYY

MorphoSys

$46.29

1.29 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$360.53

-0.47 (-0.13%)

09:22
02/17/18
02/17
09:22
02/17/18
09:22
Hot Stocks
Lockheed Martin receives Freedom-variant FFG conceptual design contract »

The U.S. Navy awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

  • 30

    May

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

, UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

09:11
02/17/18
02/17
09:11
02/17/18
09:11
Periodicals
Bears, bulls battle over Under Armour, Barron's says »

In a follow-up story,…

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOV

Hovnanian

$2.24

0.12 (5.66%)

09:04
02/17/18
02/17
09:04
02/17/18
09:04
Periodicals
Hovnanian stock too cheap to ignore, Barron's says »

Hovnanian Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

, JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

09:00
02/17/18
02/17
09:00
02/17/18
09:00
Periodicals
JPMorgan, Walmart cash flow yields exceed dividend yields, Barron's says »

The cash flow yields of…

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 30

    May

  • 14

    Jul

  • 12

    Oct

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

, GOOG

Alphabet

$1,094.80

5.28 (0.48%)

08:56
02/17/18
02/17
08:56
02/17/18
08:56
Periodicals
Alphabet, Citi well positioned for later stages of market rally, Barron's says »

It is time for investors…

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 18

    Mar

  • 28

    Mar

  • 29

    Mar

  • 30

    May

GE

General Electric

$15.05

0.2 (1.35%)

08:48
02/17/18
02/17
08:48
02/17/18
08:48
Periodicals
General Electric stock could drop another 10%, Barron's says »

General Electric lost $6B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

, VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

08:32
02/17/18
02/17
08:32
02/17/18
08:32
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

PWR

Quanta Services

$35.07

0.24 (0.69%)

EXP

Eagle Materials

$102.75

-3.83 (-3.59%)

FLR

Fluor

$57.63

-0.22 (-0.38%)

USCR

U.S. Concrete

$78.00

-1.4 (-1.76%)

ACM

Aecom

$35.36

0.08 (0.23%)

CBI

CB&I

$18.71

0.04 (0.21%)

GVA

Granite Construction

$60.36

2.69 (4.66%)

CAT

Caterpillar

$156.29

-3.69 (-2.31%)

MLM

Martin Marietta

$216.25

-6.34 (-2.85%)

V

Visa

$121.85

-0.43 (-0.35%)

AA

Alcoa

$47.36

-0.21 (-0.44%)

ARNC

Arconic

$25.36

0.14 (0.56%)

CENX

Century Aluminum

$24.12

1.85 (8.31%)

X

U.S. Steel

$44.75

5.76 (14.77%)

STLD

Steel Dynamics

$49.40

2.26 (4.79%)

AKS

AK Steel

$5.96

0.72 (13.74%)

CLF

Cleveland-Cliffs

$7.92

0.55 (7.46%)

NUE

Nucor

$68.54

2.96 (4.51%)

MT

ArcelorMittal

$36.48

1.19 (3.37%)

TKR

Timken

$45.00

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

  • 23

    May

  • 30

    May

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
Cambridge Healthtech Institute to hold a conference »

Molecular Med Tri-Con…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MIDD

Middleby

$135.00

1.94 (1.46%)

18:01
02/16/18
02/16
18:01
02/16/18
18:01
Hot Stocks
Middleby acquires Hinds-Bock Corporation, terms not disclosed »

Middleby announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.14

0.14 (0.38%)

, TWX

Time Warner

$95.37

0.38 (0.40%)

17:37
02/16/18
02/16
17:37
02/16/18
17:37
Periodicals
Breaking Periodicals news story on AT&T, Time Warner »

Judge says to rule on …

T

AT&T

$37.14

0.14 (0.38%)

TWX

Time Warner

$95.37

0.38 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

CARS

Cars.com

$29.27

0.33 (1.14%)

17:31
02/16/18
02/16
17:31
02/16/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Cars.com »

Starboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONTX

Onconova

$1.07

0.01 (0.94%)

17:29
02/16/18
02/16
17:29
02/16/18
17:29
Hot Stocks
683 Capital reports 21.8% stake in Onconova, says shares undervalued »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$224.19

-1.21 (-0.54%)

17:26
02/16/18
02/16
17:26
02/16/18
17:26
Hot Stocks
General Dynamics awarded $148.9M government contract modification »

General Dynamics Land…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRS

Antares Pharma

$2.39

0.04 (1.70%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Breaking Hot Stocks news story on Antares Pharma »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$265.70

10.31 (4.04%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Huntington Ingalls awarded $1.43B government contract modification »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DIT

AMCON Distributing

$87.50

0.13 (0.15%)

17:24
02/16/18
02/16
17:24
02/16/18
17:24
Hot Stocks
Breaking Hot Stocks news story on AMCON Distributing »

Hale Partnership reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$41.09

-0.76 (-1.82%)

, TSLA

Tesla

$335.49

1.425 (0.43%)

17:11
02/16/18
02/16
17:11
02/16/18
17:11
Periodicals
Chevy Bolt sales bolstered by Tesla delays, tax credit worries, Reuters says »

Certain potential buyers…

GM

General Motors

$41.09

-0.76 (-1.82%)

TSLA

Tesla

$335.49

1.425 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AGN

Allergan

$164.04

-0.43 (-0.26%)

17:11
02/16/18
02/16
17:11
02/16/18
17:11
Syndicate
Breaking Syndicate news story on Allergan »

Allergan files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 25

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.